Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size

Statistics for the 2023 & 2024 Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors market size, created by Mordor Intelligence™ Industry Reports. Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors size report includes a market forecast to 2029 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 754.60 Million
Market Size (2029) USD 931.40 Million
CAGR (2024 - 2029) 4.30 %

Major Players

Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Latin America DPP-4 Inhibitors Market Analysis

The Latin America Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 754.60 million in 2024, and is expected to reach USD 931.40 million by 2029, growing at a CAGR of 4.30% during the forecast period (2024-2029).

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.

The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, nearly 10% of the population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, accounting for nearly 90% of the total diabetic population.

Mexico has multiple health insurance providers. The Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (State Employee's Social Security and Social Services Institute, ISSSTE) provides coverage for government employees, and the Instituto Mexicano del Seguro Social (Mexican Social Security Institute, IMSS) covers private-sector employees. The Seguro Popular (People's Insurance) was launched to protect the working-age population against steep healthcare costs.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Latin America DPP-4 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)